Graft-versus-host disease treatment

Recommend a prophylactic and treatment regimen for graft-versus-host disease (GVHD). 

Treatment of Acute Graft-Versus-Host Disease... 

Laurent, G., D. Maraninchi, E. Gluckman, J.P Vernant, J.M. Derocq, M.H. Gaspard, B. Rio, M. Michalet, J. Reiffers, F. Dreyfus, et al.. Donor bone marrow treatment with TlOl Fab fragment-ricin A-chain immunotoxin prevents graft-versus-host disease. Bone Marrow Transplant, 1989. 4(4) 367-71. 

G. Other applications Other possible uses of Orthoclone OKT3 are for prophylaxis and treatment of acute graft-versus-host disease (as an adjunct with allogeneic bone marrow transplantation) treatment of rejection after lung transplantation prophylaxis and treatment of rejection... 

Le Blanc, K., Rasmusson, I., Sundberg, B., et al. (2004), Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells, Lancet, 1, 363(9419), 1439-1441. 

Ringden, O., Uzunel, M., Rasmusson, I., et al. (2006), Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease, Transplantation, 81(10), 1390-1397. 

Retrovirus vectors have demonstrated some promising results in cancer therapy and bone marrow transplantation. The introduction of retrovirus particles expressing HSV-TK and administration of GCV suggested that the treatment of graft-versus-host disease was efficient (37). The demonstration of the full correction of the SCID-X1 phenotype in infants is a further indication of the efficacy of retrovirus vectors (38). 

Volume III, Pharmacology and Therapy, addresses developments in basic science, translational and clinical research that are underway to bring stem cell research to therapy, particularly for the treatment of Batten s diseases, graft-versus-host disease and adenosine deaminase deficiency. This volume covers the importance of stem cell research for the understanding of drug activities and design. It also addresses the ethical issues and constraints involved in stem cell research, and its commercial applications. 

New strategies in the treatment of graft-versus-host disease Basara, N., Blau, I.W., Willenbacher, W., Kiehl, M.G., Fauser, A. A. (2000). Bone Marrow Transplant, 25 Suppl 2 S12-S15... 

Pentostatin for the treatment of chronic graft-versus-host disease in children Goldberg, J.D., Jacobsohn, D.A., Margolis, J., Chen, A.R., Anders, V., Phelps, M., Vogelsang, G.B. (2003). JPediatr Hematol Oncol, 25 (7) 584-588. 

Bordigoni P, Dimicoli S, Clement L, Baumann C. 2006. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Hematol. 135 382-385. 

Przepiorka D, Keman NA, Ipppoliti C, Papandopoulas EB, et al. 2000. Dachzumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for the treatment of acute graft-versus-host disease Blood. 2000 83-89. 

Beckman RA, Siden R, Yanik GA, Levine JE. Continuous octreotide infusion for the treatment of secretory diarrhea caused by acute intestinal graft-versus-host disease in a child. J Pediatr Hematol Oncol 2000 22(4) 344—50. 

In the management of transplants, ALG and monoclonal antibodies can be used in the induction of immunosuppression, in the treatment of initial rejections, and in the treatment of steroid-resistant rejections. There has been some success in the use of ALG and ATG plus cyclosporine for recipient preparation for bone marrow transplantation. In this procedure, the recipient is treated with ALG or ATG in large doses for 7-10 days prior to transplantation of bone marrow cells from the donor. Residual ALG appears to destroy the T cells in the donor marrow graft, and the probability of severe graft-versus-host disease is reduced. 

Ansetti, C., Hansen, J. A., Waldmann, T. A. el al. (1994). Treatment of acute graft-versus-host disease with humanized anti-Tac An antibody that binds to the inter-leukin-2 receptor. Blood84, 1320-1327. 

---